Posted by admin on Apr 30th, 2022

Brokerages expect LeMaitre Vascular, Inc. (NASDAQ:LMAT – Get Rating) to post sales of $42.18 million for the current quarter, according to Zacks. Five analysts have issued estimates for LeMaitre Vascular’s earnings, with the highest sales estimate coming in at $43.51 million and the lowest estimate coming in at $40.80 million. LeMaitre Vascular reported sales of $40.67 million in the same quarter last year, which would suggest a positive year-over-year growth rate of 3.7%. The firm is scheduled to announce its next quarterly earnings report on Monday, January 1st.

On average, analysts expect that LeMaitre Vascular will report full-year sales of $164.26 million for the current year, with estimates ranging from $164.00 million to $165.12 million. For the next year, analysts expect that the firm will report sales of $174.42 million, with estimates ranging from $171.92 million to $178.07 million. Zacks’ sales averages are a mean average based on a survey of sell-side analysts that follow LeMaitre Vascular.

LeMaitre Vascular (NASDAQ:LMAT – Get Rating) last released its quarterly earnings results on Thursday, April 28th. The medical instruments supplier reported $0.27 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $0.28 by ($0.01). The firm had revenue of $39.56 million for the quarter, compared to analyst estimates of $38.65 million. LeMaitre Vascular had a return on equity of 12.42% and a net margin of 17.42%. The business’s revenue for the quarter was up 10.2% on a year-over-year basis. During the same period in the previous year, the business posted $0.28 earnings per share.

Several analysts recently weighed in on the company. StockNews.com assumed coverage on LeMaitre Vascular in a report on Thursday, March 31st. They set a “hold” rating for the company. Barrington Research cut their target price on LeMaitre Vascular from $54.00 to $50.00 in a research report on Friday. Finally, Zacks Investment Research upgraded LeMaitre Vascular from a “hold” rating to a “buy” rating and set a $50.00 target price for the company in a research report on Thursday. Two analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. According to MarketBeat, the company has a consensus rating of “Buy” and an average target price of $58.60.

NASDAQ:LMAT opened at $43.21 on Friday. The stock has a market cap of $948.55 million, a P/E ratio of 34.29, a PEG ratio of 3.39 and a beta of 1.32. The stock has a 50 day simple moving average of $45.73 and a 200 day simple moving average of $47.50. LeMaitre Vascular has a 1-year low of $39.48 and a 1-year high of $64.50.

The business also recently announced a quarterly dividend, which was paid on Thursday, March 24th. Stockholders of record on Tuesday, March 8th were given a dividend of $0.125 per share. This represents a $0.50 dividend on an annualized basis and a dividend yield of 1.16%. This is an increase from LeMaitre Vascular’s previous quarterly dividend of $0.11. The ex-dividend date of this dividend was Monday, March 7th. LeMaitre Vascular’s dividend payout ratio is presently 39.68%.

In related news, insider Trent G. Kamke sold 7,929 shares of the company’s stock in a transaction on Wednesday, March 2nd. The stock was sold at an average price of $48.22, for a total transaction of $382,336.38. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 16.50% of the company’s stock.

A number of institutional investors and hedge funds have recently modified their holdings of the business. BlackRock Inc. increased its stake in shares of LeMaitre Vascular by 5.9% in the third quarter. BlackRock Inc. now owns 3,115,834 shares of the medical instruments supplier’s stock valued at $165,420,000 after buying an additional 173,671 shares during the period. Copeland Capital Management LLC increased its stake in shares of LeMaitre Vascular by 7.1% in the fourth quarter. Copeland Capital Management LLC now owns 1,205,199 shares of the medical instruments supplier’s stock valued at $60,537,000 after buying an additional 80,112 shares during the period. Summit Creek Advisors LLC increased its stake in shares of LeMaitre Vascular by 21.0% in the fourth quarter. Summit Creek Advisors LLC now owns 361,359 shares of the medical instruments supplier’s stock valued at $18,151,000 after buying an additional 62,754 shares during the period. Renaissance Technologies LLC increased its stake in shares of LeMaitre Vascular by 123.8% in the third quarter. Renaissance Technologies LLC now owns 103,500 shares of the medical instruments supplier’s stock valued at $5,495,000 after buying an additional 57,261 shares during the period. Finally, ProShare Advisors LLC increased its stake in shares of LeMaitre Vascular by 26.3% in the fourth quarter. ProShare Advisors LLC now owns 207,271 shares of the medical instruments supplier’s stock valued at $10,412,000 after buying an additional 43,213 shares during the period. 85.82% of the stock is owned by institutional investors and hedge funds.

About LeMaitre Vascular (Get Rating)

LeMaitre Vascular, Inc designs, markets, sells, services, and supports medical devices and implants for the treatment of peripheral vascular disease worldwide. It offers angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries or veins; occlusion catheters that temporarily occlude the blood flow; perfusion catheters to perfuse the blood and other fluids into the vasculature; and thrombectomy catheters, which features a silicone balloon for removing thrombi in the venous system.

Get a free copy of the Zacks research report on LeMaitre Vascular (LMAT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for LeMaitre Vascular Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LeMaitre Vascular and related companies with MarketBeat.com's FREE daily email newsletter.

Analysts Expect Berkshire Hills Bancorp, Inc. (NYSE:BHLB) Will Announce Quarterly Sales of $96.00 Million

Analysts Anticipate Medical Properties Trust, Inc. (NYSE:MPW) Will Post Quarterly Sales of $405.73 Million